APO Research
Talk to an analyst

APO RESEARCH · REPORT

Recurrent Urinary Tract Infection Treatment

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Recurrent Urinary Tract Infection Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

4 July 2026182 pages

Choose your research edition.

Industry ResearchRecurrent Urinary Tract Infection Treatment Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Recurrent Urinary Tract Infection Treatment Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Recurrent Urinary Tract Infection Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recurrent Urinary Tract Infection Treatment Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Recurrent Urinary Tract Infection Treatment Market Analysis and Forecast 2026-2032171 pages · $4,950 USD

Market perspective

The global Recurrent Urinary Tract Infection Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Recurrent Urinary Tract Infection Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recurrent Urinary Tract Infection Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recurrent Urinary Tract Infection Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Recurrent Urinary Tract Infection Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Recurrent Urinary Tract Infection Treatment include Bayer AG, GlaxoSmithKline Pharmaceuticals Ltd., Pfizer, Allergan Plc, Almirall SA, Bristol-Myers Squibb and Merck & Co., Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Recurrent Urinary Tract Infection Treatment market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recurrent Urinary Tract Infection Treatment and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recurrent Urinary Tract Infection Treatment revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Recurrent Urinary Tract Infection Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Recurrent Urinary Tract Infection Treatment Segment by Company

Bayer AG

GlaxoSmithKline Pharmaceuticals Ltd.

Pfizer

Allergan Plc

Almirall SA

Bristol-Myers Squibb

Merck & Co., Inc.

Recurrent Urinary Tract Infection Treatment Segment by Type

Pharmaceuticals

Services

Recurrent Urinary Tract Infection Treatment Segment by Application

Hospital Pharmacies

Specialty Clinics

Others

Recurrent Urinary Tract Infection Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recurrent Urinary Tract Infection Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recurrent Urinary Tract Infection Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recurrent Urinary Tract Infection Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Recurrent Urinary Tract Infection Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Recurrent Urinary Tract Infection Treatment industry.

Chapter 3: Detailed analysis of Recurrent Urinary Tract Infection Treatment companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Recurrent Urinary Tract Infection Treatmentrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Recurrent Urinary Tract Infection Treatment Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Pharmaceuticals Table 3. Key Players of Services Table 4. Global Recurrent Urinary Tract Infection Treatment Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Hospital Pharmacies Table 6. Key Players of Specialty Clinics Table 7. Key Players of Others Table 8. Global Recurrent Urinary Tract Infection Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Recurrent Urinary Tract Infection Treatment Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Recurrent Urinary Tract Infection Treatment Market Share by Region (2021-2026) Table 11. Global Recurrent Urinary Tract Infection Treatment Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Recurrent Urinary Tract Infection Treatment Market Share by Region (2027-2032) Table 13. Recurrent Urinary Tract Infection Treatment Industry Trends Table 14. Recurrent Urinary Tract Infection Treatment Industry Drivers Table 15. Recurrent Urinary Tract Infection Treatment Industry Opportunities and Challenges Table 16. Recurrent Urinary Tract Infection Treatment Industry Restraints Table 17. Global Recurrent Urinary Tract Infection Treatment Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Recurrent Urinary Tract Infection Treatment Revenue Market Share by Company (2021-2026) Table 19. Global Recurrent Urinary Tract Infection Treatment Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Recurrent Urinary Tract Infection Treatment Key Company Head Office and Area Served Table 21. Global Recurrent Urinary Tract Infection Treatment Company, Product Type & Application Table 22. Global Recurrent Urinary Tract Infection Treatment Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Recurrent Urinary Tract Infection Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Recurrent Urinary Tract Infection Treatment Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Recurrent Urinary Tract Infection Treatment Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Recurrent Urinary Tract Infection Treatment Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Recurrent Urinary Tract Infection Treatment Revenue Market Share by Type (2021-2026) Table 29. Global Recurrent Urinary Tract Infection Treatment Revenue Market Share by Type (2027-2032) Table 30. Global Recurrent Urinary Tract Infection Treatment Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Recurrent Urinary Tract Infection Treatment Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Recurrent Urinary Tract Infection Treatment Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Recurrent Urinary Tract Infection Treatment Revenue Market Share by Application (2021-2026) Table 34. Global Recurrent Urinary Tract Infection Treatment Revenue Market Share by Application (2027-2032) Table 35. Bayer AG Company Information Table 36. Bayer AG Business Overview Table 37. Bayer AG Recurrent Urinary Tract Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Bayer AG Recurrent Urinary Tract Infection Treatment Product Portfolio Table 39. Bayer AG Recent Development Table 40. GlaxoSmithKline Pharmaceuticals Ltd. Company Information Table 41. GlaxoSmithKline Pharmaceuticals Ltd. Business Overview Table 42. GlaxoSmithKline Pharmaceuticals Ltd. Recurrent Urinary Tract Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. GlaxoSmithKline Pharmaceuticals Ltd. Recurrent Urinary Tract Infection Treatment Product Portfolio Table 44. GlaxoSmithKline Pharmaceuticals Ltd. Recent Development Table 45. Pfizer Company Information Table 46. Pfizer Business Overview Table 47. Pfizer Recurrent Urinary Tract Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Pfizer Recurrent Urinary Tract Infection Treatment Product Portfolio Table 49. Pfizer Recent Development Table 50. Allergan Plc Company Information Table 51. Allergan Plc Business Overview Table 52. Allergan Plc Recurrent Urinary Tract Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Allergan Plc Recurrent Urinary Tract Infection Treatment Product Portfolio Table 54. Allergan Plc Recent Development Table 55. Almirall SA Company Information Table 56. Almirall SA Business Overview Table 57. Almirall SA Recurrent Urinary Tract Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Almirall SA Recurrent Urinary Tract Infection Treatment Product Portfolio Table 59. Almirall SA Recent Development Table 60. Bristol-Myers Squibb Company Information Table 61. Bristol-Myers Squibb Business Overview Table 62. Bristol-Myers Squibb Recurrent Urinary Tract Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Bristol-Myers Squibb Recurrent Urinary Tract Infection Treatment Product Portfolio Table 64. Bristol-Myers Squibb Recent Development Table 65. Merck & Co., Inc. Company Information Table 66. Merck & Co., Inc. Business Overview Table 67. Merck & Co., Inc. Recurrent Urinary Tract Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Merck & Co., Inc. Recurrent Urinary Tract Infection Treatment Product Portfolio Table 69. Merck & Co., Inc. Recent Development Table 70. North America Recurrent Urinary Tract Infection Treatment Market Size by Type (2021-2026) & (US$ Million) Table 71. North America Recurrent Urinary Tract Infection Treatment Market Size by Type (2027-2032) & (US$ Million) Table 72. North America Recurrent Urinary Tract Infection Treatment Market Size by Application (2021-2026) & (US$ Million) Table 73. North America Recurrent Urinary Tract Infection Treatment Market Size by Application (2027-2032) & (US$ Million) Table 74. North America Recurrent Urinary Tract Infection Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 75. North America Recurrent Urinary Tract Infection Treatment Market Size by Country (2021-2026) Table 76. North America Recurrent Urinary Tract Infection Treatment Market Size by Country (2027-2032) Table 77. Europe Recurrent Urinary Tract Infection Treatment Market Size by Type (2021-2026) & (US$ Million) Table 78. Europe Recurrent Urinary Tract Infection Treatment Market Size by Type (2027-2032) & (US$ Million) Table 79. Europe Recurrent Urinary Tract Infection Treatment Market Size by Application (2021-2026) & (US$ Million) Table 80. Europe Recurrent Urinary Tract Infection Treatment Market Size by Application (2027-2032) & (US$ Million) Table 81. Europe Recurrent Urinary Tract Infection Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 82. Europe Recurrent Urinary Tract Infection Treatment Market Size by Country (2021-2026) Table 83. Europe Recurrent Urinary Tract Infection Treatment Market Size by Country (2027-2032) Table 84. China Recurrent Urinary Tract Infection Treatment Market Size by Type (2021-2026) & (US$ Million) Table 85. China Recurrent Urinary Tract Infection Treatment Market Size by Type (2027-2032) & (US$ Million) Table 86. China Recurrent Urinary Tract Infection Treatment Market Size by Application (2021-2026) & (US$ Million) Table 87. China Recurrent Urinary Tract Infection Treatment Market Size by Application (2027-2032) & (US$ Million) Table 88. Asia Recurrent Urinary Tract Infection Treatment Market Size by Type (2021-2026) & (US$ Million) Table 89. Asia Recurrent Urinary Tract Infection Treatment Market Size by Type (2027-2032) & (US$ Million) Table 90. Asia Recurrent Urinary Tract Infection Treatment Market Size by Application (2021-2026) & (US$ Million) Table 91. Asia Recurrent Urinary Tract Infection Treatment Market Size by Application (2027-2032) & (US$ Million) Table 92. Asia Recurrent Urinary Tract Infection Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 93. Asia Recurrent Urinary Tract Infection Treatment Market Size by Country (2021-2026) Table 94. Asia Recurrent Urinary Tract Infection Treatment Market Size by Country (2027-2032) Table 95. South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Size by Type (2021-2026) & (US$ Million) Table 96. South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Size by Type (2027-2032) & (US$ Million) Table 97. South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Size by Application (2021-2026) & (US$ Million) Table 98. South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Size by Application (2027-2032) & (US$ Million) Table 99. South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Size by Country (2021-2026) Table 101. South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Size by Country (2027-2032) Table 102. Research Programs/Design for This Report Table 103. Authors List of This Report Table 104. Secondary Sources Table 105. Primary Sources List of Figures Figure 1. Recurrent Urinary Tract Infection Treatment Product Image Figure 2. Global Recurrent Urinary Tract Infection Treatment Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Recurrent Urinary Tract Infection Treatment Market Share by Type: 2025 VS 2032 Figure 4. Pharmaceuticals Image Figure 5. Services Image Figure 6. Global Recurrent Urinary Tract Infection Treatment Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 7. Global Recurrent Urinary Tract Infection Treatment Market Share by Application: 2025 VS 2032 Figure 8. Hospital Pharmacies Image Figure 9. Specialty Clinics Image Figure 10. Others Image Figure 11. Global Recurrent Urinary Tract Infection Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 13. Global Recurrent Urinary Tract Infection Treatment Market Share by Region: 2025 VS 2032 Figure 14. Years Considered Figure 15. Global Recurrent Urinary Tract Infection Treatment Market Share by Players in 2025 Figure 16. Global Top 5 and 10 Recurrent Urinary Tract Infection Treatment Players Market Share by Revenue in 2025 Figure 17. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Recurrent Urinary Tract Infection Treatment Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Recurrent Urinary Tract Infection Treatment Revenue Market Share by Type (2021-2032) Figure 20. Global Recurrent Urinary Tract Infection Treatment Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Recurrent Urinary Tract Infection Treatment Revenue Market Share by Application (2021-2032) Figure 22. North America Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 23. North America Recurrent Urinary Tract Infection Treatment Market Share by Type (2021-2032) Figure 24. North America Recurrent Urinary Tract Infection Treatment Market Share by Application (2021-2032) Figure 25. North America Recurrent Urinary Tract Infection Treatment Market Share by Country (2021-2032) Figure 26. United States Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 27. Canada Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 28. Mexico Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 29. Europe Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 30. Europe Recurrent Urinary Tract Infection Treatment Market Share by Type (2021-2032) Figure 31. Europe Recurrent Urinary Tract Infection Treatment Market Share by Application (2021-2032) Figure 32. Europe Recurrent Urinary Tract Infection Treatment Market Share by Country (2021-2032) Figure 33. Germany Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 34. France Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 35. U.K. Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 36. Italy Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 37. Russia Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 38. Nordic Countries Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 39. China Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 40. China Recurrent Urinary Tract Infection Treatment Market Share by Type (2021-2032) Figure 41. China Recurrent Urinary Tract Infection Treatment Market Share by Application (2021-2032) Figure 42. Asia Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 43. Asia Recurrent Urinary Tract Infection Treatment Market Share by Type (2021-2032) Figure 44. Asia Recurrent Urinary Tract Infection Treatment Market Share by Application (2021-2032) Figure 45. Asia Recurrent Urinary Tract Infection Treatment Market Share by Country (2021-2032) Figure 46. Japan Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 47. South Korea Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 48. Taiwan Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 49. Southeast Asia Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 50. India Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 51. Australia Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 52. South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Share by Type (2021-2032) Figure 54. South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Share by Application (2021-2032) Figure 55. South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Share by Country (2021-2032) Figure 56. Brazil Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 57. South Africa Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 58. Saudi Arabia Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 59. Turkey Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 60. Argentina Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 61. UAE Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 62. Egypt Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 63. Chile Recurrent Urinary Tract Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 64. Research Process Figure 65. Key Executives Interviewed

Scope & coverage.

Types
  • Pharmaceuticals
  • Services
Applications
  • Hospital Pharmacies
  • Specialty Clinics
  • Others
Companies covered
  • Bayer AG
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • Pfizer
  • Allergan Plc
  • Almirall SA
  • Bristol-Myers Squibb
  • Merck & Co., Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Recurrent Urinary Tract Infection Treatment Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Pharmaceuticals
  5. 1.2.3 Services
  6. 1.3 Market Analysis by Application
  7. 1.3.1 Global Recurrent Urinary Tract Infection Treatment Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital Pharmacies
  9. 1.3.3 Specialty Clinics
  10. 1.3.4 Others
  11. 1.4 Global Market Growth Prospects
  12. 1.5 Global Recurrent Urinary Tract Infection Treatment Growth Trends by Region
  13. 1.5.1 Global Recurrent Urinary Tract Infection Treatment Market Size by Region: 2021 VS 2025 VS 2032
  14. 1.5.2 Recurrent Urinary Tract Infection Treatment Market Size by Region (2021-2026)
  15. 1.5.3 Recurrent Urinary Tract Infection Treatment Market Size by Region (2027-2032)
  16. 1.6 Assumptions and Limitations
  17. 1.7 Study Goals and Objectives
  18. 1.8 Years Considered
2 Global Recurrent Urinary Tract Infection Treatment Market Dynamics
  1. 2.1 Recurrent Urinary Tract Infection Treatment Industry Trends
  2. 2.2 Recurrent Urinary Tract Infection Treatment Industry Drivers
  3. 2.3 Recurrent Urinary Tract Infection Treatment Industry Opportunities and Challenges
  4. 2.4 Recurrent Urinary Tract Infection Treatment Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Recurrent Urinary Tract Infection Treatment Revenue by Company (2021-2026)
  2. 3.2 Global Recurrent Urinary Tract Infection Treatment Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Recurrent Urinary Tract Infection Treatment Key Company Head office and Area Served
  4. 3.4 Global Recurrent Urinary Tract Infection Treatment Company, Product Type & Application
  5. 3.5 Global Recurrent Urinary Tract Infection Treatment Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Recurrent Urinary Tract Infection Treatment Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Recurrent Urinary Tract Infection Treatment Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Recurrent Urinary Tract Infection Treatment Tier 1, Tier 2, and Tier 3
4 Recurrent Urinary Tract Infection Treatment Market by Type
  1. 4.1 Global Recurrent Urinary Tract Infection Treatment Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Recurrent Urinary Tract Infection Treatment Market Size by Type (2021-2032)
  3. 4.3 Global Recurrent Urinary Tract Infection Treatment Market Size Share by Type (2021-2032)
5 Recurrent Urinary Tract Infection Treatment Market by Application
  1. 5.1 Global Recurrent Urinary Tract Infection Treatment Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Recurrent Urinary Tract Infection Treatment Market Size by Application (2021-2032)
  3. 5.3 Global Recurrent Urinary Tract Infection Treatment Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Bayer AG
  2. 6.1.1 Bayer AG Company Information
  3. 6.1.2 Bayer AG Business Overview
  4. 6.1.3 Bayer AG Recurrent Urinary Tract Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Bayer AG Recurrent Urinary Tract Infection Treatment Product Portfolio
  6. 6.1.5 Bayer AG Recent Developments
  7. 6.2 GlaxoSmithKline Pharmaceuticals Ltd.
  8. 6.2.1 GlaxoSmithKline Pharmaceuticals Ltd. Company Information
  9. 6.2.2 GlaxoSmithKline Pharmaceuticals Ltd. Business Overview
  10. 6.2.3 GlaxoSmithKline Pharmaceuticals Ltd. Recurrent Urinary Tract Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 GlaxoSmithKline Pharmaceuticals Ltd. Recurrent Urinary Tract Infection Treatment Product Portfolio
  12. 6.2.5 GlaxoSmithKline Pharmaceuticals Ltd. Recent Developments
  13. 6.3 Pfizer
  14. 6.3.1 Pfizer Company Information
  15. 6.3.2 Pfizer Business Overview
  16. 6.3.3 Pfizer Recurrent Urinary Tract Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Pfizer Recurrent Urinary Tract Infection Treatment Product Portfolio
  18. 6.3.5 Pfizer Recent Developments
  19. 6.4 Allergan Plc
  20. 6.4.1 Allergan Plc Company Information
  21. 6.4.2 Allergan Plc Business Overview
  22. 6.4.3 Allergan Plc Recurrent Urinary Tract Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Allergan Plc Recurrent Urinary Tract Infection Treatment Product Portfolio
  24. 6.4.5 Allergan Plc Recent Developments
  25. 6.5 Almirall SA
  26. 6.5.1 Almirall SA Company Information
  27. 6.5.2 Almirall SA Business Overview
  28. 6.5.3 Almirall SA Recurrent Urinary Tract Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Almirall SA Recurrent Urinary Tract Infection Treatment Product Portfolio
  30. 6.5.5 Almirall SA Recent Developments
  31. 6.6 Bristol-Myers Squibb
  32. 6.6.1 Bristol-Myers Squibb Company Information
  33. 6.6.2 Bristol-Myers Squibb Business Overview
  34. 6.6.3 Bristol-Myers Squibb Recurrent Urinary Tract Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Bristol-Myers Squibb Recurrent Urinary Tract Infection Treatment Product Portfolio
  36. 6.6.5 Bristol-Myers Squibb Recent Developments
  37. 6.7 Merck & Co., Inc.
  38. 6.7.1 Merck & Co., Inc. Company Information
  39. 6.7.2 Merck & Co., Inc. Business Overview
  40. 6.7.3 Merck & Co., Inc. Recurrent Urinary Tract Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Merck & Co., Inc. Recurrent Urinary Tract Infection Treatment Product Portfolio
  42. 6.7.5 Merck & Co., Inc. Recent Developments
7 North America
  1. 7.1 North America Recurrent Urinary Tract Infection Treatment Market Size (2021-2032)
  2. 7.2 North America Recurrent Urinary Tract Infection Treatment Market Size by Type
  3. 7.2.1 North America Recurrent Urinary Tract Infection Treatment Market Size by Type (2021-2026)
  4. 7.2.2 North America Recurrent Urinary Tract Infection Treatment Market Size by Type (2027-2032)
  5. 7.2.3 North America Recurrent Urinary Tract Infection Treatment Market Share by Type (2021-2032)
  6. 7.3 North America Recurrent Urinary Tract Infection Treatment Market Size by Application
  7. 7.3.1 North America Recurrent Urinary Tract Infection Treatment Market Size by Application (2021-2026)
  8. 7.3.2 North America Recurrent Urinary Tract Infection Treatment Market Size by Application (2027-2032)
  9. 7.3.3 North America Recurrent Urinary Tract Infection Treatment Market Share by Application (2021-2032)
  10. 7.4 North America Recurrent Urinary Tract Infection Treatment Market Size by Country
  11. 7.4.1 North America Recurrent Urinary Tract Infection Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Recurrent Urinary Tract Infection Treatment Market Size by Country (2021-2026)
  13. 7.4.3 North America Recurrent Urinary Tract Infection Treatment Market Size by Country (2027-2032)
  14. 7.4.4 North America Recurrent Urinary Tract Infection Treatment Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Recurrent Urinary Tract Infection Treatment Market Size (2021-2032)
  2. 8.2 Europe Recurrent Urinary Tract Infection Treatment Market Size by Type
  3. 8.2.1 Europe Recurrent Urinary Tract Infection Treatment Market Size by Type (2021-2026)
  4. 8.2.2 Europe Recurrent Urinary Tract Infection Treatment Market Size by Type (2027-2032)
  5. 8.2.3 Europe Recurrent Urinary Tract Infection Treatment Market Share by Type (2021-2032)
  6. 8.3 Europe Recurrent Urinary Tract Infection Treatment Market Size by Application
  7. 8.3.1 Europe Recurrent Urinary Tract Infection Treatment Market Size by Application (2021-2026)
  8. 8.3.2 Europe Recurrent Urinary Tract Infection Treatment Market Size by Application (2027-2032)
  9. 8.3.3 Europe Recurrent Urinary Tract Infection Treatment Market Share by Application (2021-2032)
  10. 8.4 Europe Recurrent Urinary Tract Infection Treatment Market Size by Country
  11. 8.4.1 Europe Recurrent Urinary Tract Infection Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Recurrent Urinary Tract Infection Treatment Market Size by Country (2021-2026)
  13. 8.4.3 Europe Recurrent Urinary Tract Infection Treatment Market Size by Country (2027-2032)
  14. 8.4.4 Europe Recurrent Urinary Tract Infection Treatment Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Recurrent Urinary Tract Infection Treatment Market Size (2021-2032)
  2. 9.2 China Recurrent Urinary Tract Infection Treatment Market Size by Type
  3. 9.2.1 China Recurrent Urinary Tract Infection Treatment Market Size by Type (2021-2026)
  4. 9.2.2 China Recurrent Urinary Tract Infection Treatment Market Size by Type (2027-2032)
  5. 9.2.3 China Recurrent Urinary Tract Infection Treatment Market Share by Type (2021-2032)
  6. 9.3 China Recurrent Urinary Tract Infection Treatment Market Size by Application
  7. 9.3.1 China Recurrent Urinary Tract Infection Treatment Market Size by Application (2021-2026)
  8. 9.3.2 China Recurrent Urinary Tract Infection Treatment Market Size by Application (2027-2032)
  9. 9.3.3 China Recurrent Urinary Tract Infection Treatment Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Recurrent Urinary Tract Infection Treatment Market Size (2021-2032)
  2. 10.2 Asia Recurrent Urinary Tract Infection Treatment Market Size by Type
  3. 10.2.1 Asia Recurrent Urinary Tract Infection Treatment Market Size by Type (2021-2026)
  4. 10.2.2 Asia Recurrent Urinary Tract Infection Treatment Market Size by Type (2027-2032)
  5. 10.2.3 Asia Recurrent Urinary Tract Infection Treatment Market Share by Type (2021-2032)
  6. 10.3 Asia Recurrent Urinary Tract Infection Treatment Market Size by Application
  7. 10.3.1 Asia Recurrent Urinary Tract Infection Treatment Market Size by Application (2021-2026)
  8. 10.3.2 Asia Recurrent Urinary Tract Infection Treatment Market Size by Application (2027-2032)
  9. 10.3.3 Asia Recurrent Urinary Tract Infection Treatment Market Share by Application (2021-2032)
  10. 10.4 Asia Recurrent Urinary Tract Infection Treatment Market Size by Country
  11. 10.4.1 Asia Recurrent Urinary Tract Infection Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Recurrent Urinary Tract Infection Treatment Market Size by Country (2021-2026)
  13. 10.4.3 Asia Recurrent Urinary Tract Infection Treatment Market Size by Country (2027-2032)
  14. 10.4.4 Asia Recurrent Urinary Tract Infection Treatment Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Recurrent Urinary Tract Infection Treatment Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst